絞り込み

16603

広告

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.

著者 Brown JD , Shewale AR , Talbert JC
J Manag Care Spec Pharm.2016 Nov ; 22(11):1319-1329.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (249view , 0users)

Full Text Sources

Medical

Non-vitamin K antagonist oral anticoagulants (NOACs) are widely used for prevention of stroke secondary to nonvalvular atrial fibrillation (NVAF). Increased use of NOACs is partially a result of simplified regimens compared with warfarin, which has been associated with poor adherence and persistence to therapy. Few studies have assessed adherence to NOACs, especially using contemporary data now that multiple NOACs are available.
PMID: 27783556 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード